▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4074 by analyst upside · 2026-08-14
BIO
Bio-Rad Laboratories, Inc.
Healthcare · Market Cap $10B · P/E 43.9x
ANALYST PRICE TARGET
-8.9%
implied upside to consensus target
Current Price $361.19
Consensus Target $329.0
Bull Target $390.0
Bear Target $280.0
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
0
Hold
3
Sell
1
52-Week Low $236.73
52-Week High $364.0
YTD Return +18.3%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) 43.9x
Forward P/E 36.0x
EPS (TTM) $8.22
PEG Ratio 4.01
Dividend Yield N/A
Revenue (TTM) $2.6B
Profit Margin 8.6%
52-WEEK RANGE
52-Week Low $236.73
52-Week High $364.0
Current Price $361.19
Bear Target $280.0
Bull Target $390.0
● Now $361.19 ● Target $329.0
TRADING DATA
Avg Volume 362K
YTD Return +18.3%
Analyst Count 5
Consensus Hold
Upside to Target -8.9%
Last Updated 2026-08-14

ANALYST SUMMARY

Bio-Rad Laboratories, Inc. (BIO) is currently trading at $361.19 with a Wall Street consensus price target of $329.0, which is 8.9% below the current price over the next 12 months. 5 analysts currently cover BIO, with a consensus rating of Hold - 20% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $390.0, while the most cautious has a target of $280.0.

BIO operates in the Healthcare sector with a market capitalisation of $10B. The stock is up 18.3% year-to-date and is currently trading near the upper end of its 52-week range of $236.73 – $364.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

STVN +14.9%
Stevanato Group S.p.A.
$6B · P/E 37.8x · Buy
HSIC +8.3%
Henry Schein, Inc.
$10B · P/E 26.3x · Buy
MEDP +-0.0%
Medpace Holdings, Inc.
$16B · P/E 34.2x · Hold
CHE +2.8%
Chemed Corporation
$7B · P/E 27.0x · Hold
ATR +28.3%
AptarGroup, Inc.
$8B · P/E 23.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BIO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-05-01 Building track record
Citigroup ↓ Downgrade
Buy → Neutral 2026-04-07 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-02-16 Building track record
Citigroup - Reiterated
Buy → Buy 2025-10-30 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2025-10-30 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2025-08-01 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2025-08-01 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2025-06-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
14/30
Consensus clarity
24/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →